



**CMMH/BSE/2026-27/36**

**August 11, 2026**

To,

The Corporate Service Department,  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai – 400 001.

**Scrip Code: 523489**

**Subject: Outcome of Board Meeting held on 11<sup>th</sup> August 2026**

**Ref: Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

We wish to inform you that the Board of Directors of the Company at its meeting held today, i.e., 11<sup>th</sup> August 2026, which commenced at 11.30 AM and concluded at 3.15 PM inter-alia, considered and approved the following:

1. The unaudited Financial Results comprising the statement of profit & loss for the quarter ended 30<sup>th</sup> June, 2026 along with the Limited Review Report submitted by the Statutory Auditors of the Company, as required under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as **Annexure A**.
2. This is to inform that on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company in its meeting held Tuesday, 11<sup>th</sup> August 2026 have approved the following:
  - i) The appointment of Dr Thanigai Vendan Moorrthy (PAN: ADUPT0825B) as Chief Executive Officer (in Non-Director Capacity) and Key Managerial Personnel (KMP) of the Company, for a term of 5 (five) consecutive years with effect from 11<sup>th</sup> August 2026. The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure B**.
  - ii) The appointment of Mr. A F Simeon Telfer (DIN: 11879121) as an Additional Director in the capacity of Non-Executive Independent Director of the Company for a term of 5 consecutive years with effect from 11<sup>th</sup> August 2026, subject to the approval of the shareholders of the Company at the

**CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LTD.**  
(Formerly Known as Devaki Hospital Limited)

**ISO 9001 : 2008 / ISO 14001 : 2004 CERTIFIED HOSPITAL**

Old No.149, New No. 70, Luz Church Road, Mylapore, Chennai - 600 004.

Ph: +91 44 - 42 938 938 | Fax: +91 44 - 2499 3282 | cmmhospitals@gmail.com | www.cmmhospitals.com

CIN: L85110TN1990PLC019545

GSTIN: 33AAACD2694N1ZF



ensuing Annual General Meeting. The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure C**.

- iii) The appointment of Mr. R V Ramanuja Bharathi (DIN: 08553270) as an Additional Director in the capacity of Non-Executive Independent Director of the Company for a term of 5 consecutive years with effect from 11<sup>th</sup> August 2026, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting. The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure D**.
- iv) The appointment of Ms. Sindu Chawla (DIN: 11879201) as an Additional Director in the capacity of Non-Executive Independent Director of the Company for a term of 5 consecutive years with effect from 11<sup>th</sup> August 2026, subject to the approval of the shareholders of the Company at the ensuing Annual General Meeting. The details required under Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as **Annexure E**.

3. Reconstitution of Committees of the Board:

Consequent to the appointment of 3 Independent (Additional) Directors, the Board of Directors has approved the reconstitution of the following Committees of the Board with effect from 11<sup>th</sup> August 2026:

- Audit Committee
- Stakeholders Relationship Committee

In compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 and SEBI (LODR) Regulations, 2015, the required disclosures containing details of the reconstituted composition of the Committees is enclosed as **Annexure-F**.

Kindly take the above information on record.

Thanking you.

Yours Faithfully,

For **CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED**

*M S Ananthalakshmi*

**M.S. Ananthalakshmi SHMI**  
**Company Secretary & Compliance Officer**  
**M No: A46694**

MS  
ANANTHALAKSHMI  
SHMI

Digitally signed by M  
S ANANTHALAKSHMI  
Date: 2026.08.11  
15:39:56 +05'30'



Encl.: As above

**CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED**

(Formerly known as Devaki Hospital Limited)

CIN:L85110TN1990PLC019545

Regd. Office: New No.70 (Old No.149), Luz Church Road, Mylapore, Chennai -600004

Phone:+91 44 42938938, Fax:+91 44 24993282, E-mail: cmmhospitals@gmail.com, Website: www.cmmh.in

**Statement of Unaudited Standalone financial results for the quarter ended 30th June,2026**

pees in lakhs except for E

| Sl. No.   | Particulars                                                                                                                     | Quarter Ended |                | Year ended     |                 |
|-----------|---------------------------------------------------------------------------------------------------------------------------------|---------------|----------------|----------------|-----------------|
|           |                                                                                                                                 | 30.06.2026    | 31.03.2026     | 30.06.2025     | 31.03.2026      |
|           |                                                                                                                                 | Unaudited     | Audited        | Unaudited      | Audited         |
| <b>1</b>  | <b>Revenue</b>                                                                                                                  |               |                |                |                 |
|           | a) Revenue from Operations                                                                                                      | 859.02        | 981.05         | 864.90         | 3703.90         |
|           | b) Other Income                                                                                                                 | 11.44         | 23.91          | 26.98          | 111.76          |
|           | <b>Total Income (1)</b>                                                                                                         | <b>870.46</b> | <b>1004.96</b> | <b>891.88</b>  | <b>3815.66</b>  |
| <b>2</b>  | <b>Expenses</b>                                                                                                                 |               |                |                |                 |
|           | a) Cost of material consumed                                                                                                    | -             | -              | -              | -               |
|           | b) Purchase of Stock-in-trade                                                                                                   | 159.83        | 210.47         | 169.49         | 750.05          |
|           | c) Changes in inventories of Stock-in-trade                                                                                     | (1.35)        | 3.11           | 0.41           | 1.19            |
|           | d) Employee benefits expenses                                                                                                   | 187.89        | 233.31         | 241.61         | 972.20          |
|           | e) Finance costs                                                                                                                | 22.17         | 22.72          | 22.22          | 89.81           |
|           | f) Depreciation & amortisation expenses                                                                                         | 25.27         | 25.76          | 28.60          | 109.08          |
|           | g) Other expenses                                                                                                               | 478.16        | 508.45         | 505.14         | 2006.65         |
|           | h) Impairment on Financial Assets                                                                                               | 0.00          | 1.36           | 0.00           | 1.36            |
|           | <b>Total Expenses (2)</b>                                                                                                       | <b>871.98</b> | <b>1005.18</b> | <b>967.47</b>  | <b>3930.34</b>  |
| <b>3</b>  | <b>Profit/(Loss) before Exceptional Items (1-2)</b>                                                                             | <b>(1.52)</b> | <b>(0.22)</b>  | <b>(75.59)</b> | <b>(114.68)</b> |
| <b>4</b>  | <b>Exceptional Items</b>                                                                                                        | <b>0</b>      | <b>0</b>       | <b>0</b>       | <b>0</b>        |
| <b>5</b>  | <b>Profit/(Loss) before Tax (3+4)</b>                                                                                           | <b>(1.52)</b> | <b>(0.22)</b>  | <b>(75.59)</b> | <b>(114.68)</b> |
| <b>6</b>  | <b>Tax Expenses</b>                                                                                                             |               |                |                |                 |
|           | a) Current Tax                                                                                                                  | 0.00          | 0              | 0.00           | 0.00            |
|           | b) Deferred Tax                                                                                                                 | (1.80)        | 1.91           | (1.48)         | (2.96)          |
| <b>7</b>  | <b>Profit/(Loss) for the period from continuing operations(After Tax) (5-6)</b>                                                 | <b>0.28</b>   | <b>(2.13)</b>  | <b>(74.11)</b> | <b>(111.72)</b> |
| <b>8</b>  | <b>Profit/(Loss) from discontinued operations</b>                                                                               | <b>0.00</b>   | <b>0.00</b>    | <b>0.00</b>    | <b>0.00</b>     |
| <b>9</b>  | <b>Tax Expense of discontinued operations</b>                                                                                   | <b>0.00</b>   | <b>0.00</b>    | <b>0.00</b>    | <b>0.00</b>     |
| <b>10</b> | <b>Profit/(Loss) from discontinued operations (After Tax) (8-9)</b>                                                             | <b>0.00</b>   | <b>0.00</b>    | <b>0.00</b>    | <b>0.00</b>     |
| <b>11</b> | <b>Profit/(Loss) for the period (7+10)</b>                                                                                      | <b>0.28</b>   | <b>(2.13)</b>  | <b>(74.11)</b> | <b>(111.72)</b> |
| <b>12</b> | <b>Other Comprehensive Income /(loss)</b>                                                                                       |               |                |                |                 |
|           | Items that will not be reclassified subsequently to profit or loss                                                              |               |                |                |                 |
|           | i) Remeasurement of net defined benefit liability/ assets                                                                       | (2.37)        | 9.17           | (6.22)         | (9.48)          |
|           | ii) Income tax relating to items that will not be classied to profit or loss                                                    | 0.60          | (2.31)         | 1.57           | 2.39            |
| <b>13</b> | <b>Total Comprehensive Income for the period comprising profit/(loss) and other comprehensive income for the period (11+12)</b> | <b>(1.49)</b> | <b>4.73</b>    | <b>(78.76)</b> | <b>(118.81)</b> |
| <b>14</b> | <b>Paid up Equity Share Capital (face value Rs.10/- per share)</b>                                                              | <b>746.89</b> | <b>746.89</b>  | <b>746.89</b>  | <b>746.89</b>   |
| <b>15</b> | <b>Earning Per Share (EPS)</b>                                                                                                  |               |                |                |                 |
|           | (Face Value ofRs.10/- per share)                                                                                                |               |                |                |                 |
|           | (a) Basic EPS (in Rs.)                                                                                                          | 0.00          | (0.03)         | (0.99)         | (1.50)          |
|           | (b) Diluted EPS (in Rs.)                                                                                                        | 0.00          | (0.03)         | (0.99)         | (1.50)          |

**Notes:**

- The Entire operations of the Company relate to only one segment viz: Hospital.
- The above results have been reviewed and recommended for adoption by the Audit Committee and approved by the Board of Directors at their meeting held on 11th August,2026.
- The financial results have been prepared in accordance with Indian Accounting Standard (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules,2015, as amended from time to time and other recognised accounting practices and policies generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015 to the extent applicable.
- The Statutory Auditors have carried out a limited review of the financial results.
- Figures for the previous periods/year have been regrouped/reclassified and rearranged whenever considered necessary to confirm to the classification of current period
- The figures for the quarter ended 31st March, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date figures upto nine months of relevant financial year which were subjected to limited review by the auditors.

For and on behalf of Board of Directors of  
CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED

Place: Chennai  
Dated: 11-08-2026



*R. Gomathe*  
**GOMATHI R**  
Managing Director

**CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED**

(Formerly known as Devaki Hospital Limited)

CIN:L85110TN1990PLC019545

Regd. Office: New No. 70 (Old no.149), Luz Church Road, Mylapore, Chennai - 600 004

Phone:+91 44 42938938, Fax:+91 44 24993282, E-mail: cmmhospitals@gmail.com, Website: www.cmmh.in

**Extract of Unaudited Standalone Financial Results for the Quarter 30th June, 2026**

(Rupees in lakhs except for EPS)

| Particulars                                                                             | Quarter ended           |                       | Year ended            |
|-----------------------------------------------------------------------------------------|-------------------------|-----------------------|-----------------------|
|                                                                                         | 30.06.2026<br>Unaudited | 31.03.2026<br>Audited | 31.03.2026<br>Audited |
| Total Income from Operations (net)                                                      | 870.46                  | 1004.96               | 3815.66               |
| Net Profit / (Loss) from Ordinary Activities before tax                                 | -1.52                   | -0.22                 | -114.68               |
| Net Profit / (Loss) from Ordinary Activities after tax                                  | 0.28                    | -2.13                 | -111.72               |
| Total Comprehensive Income for the period                                               | -1.49                   | 4.73                  | -118.81               |
| Equity Share Capital (Face value of Rs.10/- per share)                                  | 746.89                  | 746.89                | 746.89                |
| Reserves (excluding Revaluation Reserve as shown in the Balance sheet of previous year) |                         |                       | -1054.43              |
| Earning Per Share (EPS) (not annualised)<br>(Face Value of Rs.10/- per share)           |                         |                       |                       |
| Basic EPS (in Rs.)                                                                      | 0.00                    | -0.03                 | -1.50                 |
| Diluted EPS (in Rs.)                                                                    | 0.00                    | -0.03                 | -1.50                 |

**Notes:**

- 1 The above results have been reviewed and recommended for adoption by the Audit Committee and approved by the Board of Directors at their meeting held on 11th August, 2026
- 2 The above is an extract of the detailed format of Financial Results for the Quarter ended 30.06.2026 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarter and Half Year ended Financial Results are available on the Stock Exchange Website ([www.bseindia.com](http://www.bseindia.com)) and on the Company's website ([www.cmmh.in](http://www.cmmh.in))

Place: Chennai  
Dated: 11th August , 2026**CHENNAI MEENAKSHI MULTISPECIALITY HOSPITAL LIMITED**  
**GOMATHI R**  
Managing Director



**INDEPENDENT AUDITOR'S REVIEW REPORT**

**On the Unaudited Quarterly Financial Results of Chennai Meenakshi Multispeciality Hospital Limited for the quarter ended June 30, 2026**, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To the Board of Directors of  
Chennai Meenakshi Multispeciality Hospital Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Chennai Meenakshi Multispeciality Hospital Limited ("the Company"), for the quarter ended June 30, 2026 ("the statement"). This Statement has been prepared by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the 'Listing Regulations'), read with the relevant circulars issued by SEBI from time to time.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on this Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of the personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34, prescribed under Section 133 of The Companies Act, 2013 as amended read with relevant rules issued thereunder, and other accounting principles and policies, generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, read with the relevant circulars issued by the SEBI, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. As described in note 6 to the Statement, the figures for the quarter ended March 31, 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures up to nine months of the relevant financial year which were subjected to limited review by us.

For Elias George & Co.  
Chartered Accountants  
Firm Regn No. 000801S



Solomon Jimmy Choolackal  
Partner  
Membership No. 245458  
UDIN:26245458UVBLZE9492

Place: Chennai  
Date: 11-08-2026

**Annexure – B**

**Information as required under Regulation 30 read with Schedule III - Para A (7B) of Part A of the Listing Regulations and SEBI Master Circular having reference SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 issued in this regard is furnished below:**

| Sr. No. | Particulars                                                                                    | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.      | Name                                                                                           | Dr Thanigai Vendan Moorrthy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 2.      | Designation                                                                                    | Chief Executive Officer (Non Director Capacity)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 3.      | Date of Appointment & Term of Appointment                                                      | <b>Date:</b> Effective from 11 <sup>th</sup> August 2026<br><b>Term:</b> Appointed for a term of 5 consecutive years until the date of resignation or retirement (whichever is earlier)                                                                                                                                                                                                                                                                                                                                                                                         |
| 4.      | Brief Profile                                                                                  | Dr Thanigai Vendan Moorrthy is an accomplished Senior Anesthesiologist and proven Healthcare Executive with over 15 years of clinical expertise combined with significant leadership experience as a Chief Executive Officer. Uniquely positioned at the intersection of high-complexity clinical medicine, operational excellence, and strategic governance. Demonstrated success in managing perioperative risk, driving hospital revenue growth, optimizing clinical workflows, and steering healthcare organizations through complex operational and regulatory landscapes. |
| 5       | Names of the listed entity in which the director holds directorship                            | Nil                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 6.      | Disclosure of relationships between directors                                                  | Dr Thanigai Vendan Moorrthy is not related to any existing Director or Key Managerial Personnel (KMP) of the Company.                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 7.      | Information as required pursuant to BSE circular by BSE Limited (Ref No. LIST/COMP/14/2018-19) | Affirmed that Dr Thanigai Vendan Moorrthy is not debarred from holding the office of Director by virtue of any SEBI order or any other authority.                                                                                                                                                                                                                                                                                                                                                                                                                               |



### Annexure – C

#### Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circulars regarding appointment of Director:

| Sr. No. | Particulars                                                                                    | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.      | Name of Director                                                                               | A F Simeon Telfer                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 2.      | DIN                                                                                            | 11879121                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 3.      | Reason for change                                                                              | Appointment as Additional Non-Executive Independent Director                                                                                                                                                                                                                                                                                                                                                                                                |
| 4.      | Date of Appointment & Term of Appointment                                                      | <p><b>Date:</b> Effective from 11<sup>th</sup> August 2026</p> <p><b>Term:</b> Appointed for a term of 5 consecutive years, and his appointment shall be subject to the approval of shareholders at the ensuing General Meeting of the Company and shall not be liable to retire by rotation.</p>                                                                                                                                                           |
| 5.      | Brief Profile                                                                                  | Mr A F Simeon Telfer is a seasoned professional and entrepreneur with extensive experience in business development, strategic planning, revenue growth, venture execution, and corporate governance. Demonstrating proven leadership throughout their career. He has successfully launched and scaled ventures, optimized operational efficiencies, and navigated market challenges to achieve key organizational objectives with innovation and integrity. |
| 6.      | Disclosure of relationships between directors                                                  | Mr A F Simeon Telfer is not related to any existing Director or Key Managerial Personnel (KMP) of the Company.                                                                                                                                                                                                                                                                                                                                              |
| 7.      | Information as required pursuant to BSE circular by BSE Limited (Ref No. LIST/COMP/14/2018-19) | Affirmed that Mr A F Simeon Telfer is not debarred from holding the office of Director by virtue of any SEBI order or any other authority.                                                                                                                                                                                                                                                                                                                  |



**Annexure – D**

**Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circulars regarding appointment of Director:**

| <b>Sr. No.</b> | <b>Particulars</b>                                                                                    | <b>Details</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|----------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.             | <b>Name of Director</b>                                                                               | R V Ramanuja Bharathi                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 2.             | <b>DIN</b>                                                                                            | 08553270                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 3.             | <b>Reason for change</b>                                                                              | Appointment as Additional Non-Executive Independent Director                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 4.             | <b>Date of Appointment &amp; Term of Appointment</b>                                                  | <b>Date:</b> Effective from 11 <sup>th</sup> August 2026<br><br><b>Term:</b> Appointed for a term of 5 consecutive years, and his appointment shall be subject to the approval of shareholders at the ensuing General Meeting of the Company and shall not be liable to retire by rotation.                                                                                                                                                                                                           |
| 5.             | <b>Brief Profile</b>                                                                                  | Mr. R V Ramanuja Bharathi is a distinguished advocate in active practice with extensive experience in legal strategy, litigation management, dispute resolution, constitutional matters, statutory compliance, and corporate law. Demonstrating proven leadership throughout their career. He has successfully represented clients across diverse judicial and quasi-judicial forums, resolved complex legal disputes, and protected key organizational interests with integrity and professionalism. |
| 6.             | <b>Disclosure of relationships between directors</b>                                                  | Mr. R V Ramanuja Bharathi is not related to any existing Director or Key Managerial Personnel (KMP) of the Company.                                                                                                                                                                                                                                                                                                                                                                                   |
| 7.             | <b>Information as required pursuant to BSE circular by BSE Limited (Ref No. LIST/COMP/14/2018-19)</b> | Affirmed that Mr. R V Ramanuja Bharathi is not debarred from holding the office of Director by virtue of any SEBI order or any other authority.                                                                                                                                                                                                                                                                                                                                                       |



## Annexure – E

### Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Circulars regarding appointment of Director:

| Sr. No. | Particulars                                                                                    | Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.      | Name of Director                                                                               | Sindu Chawla                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 2.      | DIN                                                                                            | 11879201                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 3.      | Reason for change                                                                              | Appointment as Additional Non-Executive Independent Director                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 4.      | Date of Appointment & Term of Appointment                                                      | <p><b>Date:</b> Effective from 11<sup>th</sup> August 2026</p> <p><b>Term:</b> Appointed for a term of 5 consecutive years, and his appointment shall be subject to the approval of shareholders at the ensuing General Meeting of the Company and shall not be liable to retire by rotation.</p>                                                                                                                                                                                             |
| 5.      | Brief Profile                                                                                  | Ms. Sindu Chawla is a distinguished software engineering leader with over 15 years of extensive experience in computer networking, protocol development, network architecture, and comprehensive software testing. Demonstrating proven leadership throughout their career. She has successfully architected scalable network solutions, led cross-functional engineering teams, and delivered mission-critical software products with high reliability, precision, and technical excellence. |
| 6.      | Disclosure of relationships between directors                                                  | Ms. Sindu Chawla is not related to any existing Director or Key Managerial Personnel (KMP) of the Company.                                                                                                                                                                                                                                                                                                                                                                                    |
| 7.      | Information as required pursuant to BSE circular by BSE Limited (Ref No. LIST/COMP/14/2018-19) | Affirmed that Ms. Sindu Chawla is not debarred from holding the office of Director by virtue of any SEBI order or any other authority.                                                                                                                                                                                                                                                                                                                                                        |



**Annexure – F**

**Reconstituted Composition of Committees of the Board with effect from 11<sup>th</sup> August 2026**

**Composition of Audit Committee:**

| S No. | Name of the Director        | Category                             | Designation in Committee |
|-------|-----------------------------|--------------------------------------|--------------------------|
| 1     | Mr. M. Karunakaran          | Independent - Non Executive Director | Chairman                 |
| 2     | Mr. A F Simeon Telfer       | Independent - Non Executive Director | Member                   |
| 3     | Mrs. Jayanthi Radhakrishnan | Executive Director                   | Member                   |

**Composition of Stakeholder's Relationship Committee:**

| S No. | Name of the Director      | Category                             | Designation in Committee |
|-------|---------------------------|--------------------------------------|--------------------------|
| 1     | Ms. Sindu Chawla          | Independent - Non Executive Director | Chairman                 |
| 2     | Mr. R V Ramanuja Bharathi | Independent - Non Executive Director | Member                   |
| 3     | Mr. Edward Prabhakar      | Non-Executive Director               | Member                   |

